Is DSCO a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,265 people get DSCO articles and Market Currents by email alert.

Get email alerts on DSCO »

HEADLINES:

SmithOnStocks Opines On Stocks: May 19th Edition
Smith On Stocks • Sun, May 19 • 12 Comments
Discovery Labs Announces Completion of $14.25 Million Public Offering

PR Newswire (May 15, 2013)
SmithOnStocks Opines On Recent Biotech News
Smith On Stocks • Mon, May 13 • 8 Comments
Discovery Labs Prices $14.25 Million Public Offering of Common Stock

PR Newswire (May 10, 2013)
Discovery Labs Announces Proposed Public Offering of Common Stock

PR Newswire (May 9, 2013)
Discovery Labs Reports First Quarter 2013 Financial Results

PR Newswire (May 7, 2013)
Looking For Opportunity - 5 Biotechs That Crashed
Craig Keolanui • Mon, May 6 • 13 Comments
Discovery Laboratories Stumbles
Doolan Wesley • Tue, Apr 16 • 2 Comments
Discovery Laboratories: Still Another Delay In The Surfaxin Launch
Smith On Stocks • Mon, Apr 15 • 4 Comments
Discovery Labs Receives FDA Recommendations and Request for Clarification Regarding Recently-Submitted SURFAXIN® (lucinactant) Updated Product Specifications

PR Newswire (Apr 15, 2013)
3 Biotechs With Upcoming Product Launches
Markus Aarnio • Thu, Apr 11 • 9 Comments
Discovery Laboratories: The Surfaxin Launch And Beyond
Smith On Stocks • Thu, Mar 21 • 5 Comments
Discovery Laboratories Management Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Mar 13
Discovery Labs Reports Fourth Quarter 2012 Financial Results

PR Newswire (Mar 13, 2013)
Discovery Labs to Report Fourth Quarter 2012 Results and Hold Conference Call on Wednesday, March 13, 2013

PR Newswire (Mar 6, 2013)
A Biotechnology Company Worth Speculating For
Doolan Wesley • Sun, Feb 24 • 1 Comment
Discovery Laboratories: Innovative Financing Is A Catalyst To Buy The Stock
Smith On Stocks • Thu, Feb 14 • 11 Comments
Discovery Labs Receives $30 Million Funding Commitment from Deerfield Management

PR Newswire (Feb 13, 2013)
Investment Implications Of The Acquisition Of MAP Pharmaceuticals By Allergan
Smith On Stocks • Thu, Jan 24 • 5 Comments
Discovery Labs Receives New US Patent for Pulmonary Surfactant Formulations

GlobeNewswire (Jan 17, 2013)

To learn more about Seeking Alpha Pro, click here.

Discovery Laboratories Stumbles
Doolan Wesley • Tue, Apr 16 • 2 Comments
Discovery Laboratories: Still Another Delay In The Surfaxin Launch
Smith On Stocks • Mon, Apr 15 • 4 Comments
Discovery Laboratories: The Surfaxin Launch And Beyond
Smith On Stocks • Thu, Mar 21 • 5 Comments
A Biotechnology Company Worth Speculating For
Doolan Wesley • Sun, Feb 24 • 1 Comment
Discovery Laboratories: Innovative Financing Is A Catalyst To Buy The Stock
Smith On Stocks • Thu, Feb 14 • 11 Comments
2013 Will Be A Telling Year For Discovery Laboratories
Brian L. Wilson • Wed, Jan 9 • 5 Comments
Discovery Laboratories Announces Changing Of The Guard
Smith On Stocks • Sun, Jan 6 • 4 Comments
Discovery Laboratories: Disappointment With Delay In Surfaxin Launch Creates An Opportunity
Smith On Stocks • Tue, Dec 18, 2012 • 17 Comments
Discovery Laboratories: Reiterating Buy, The Street Is Getting On Board
Smith On Stocks • Mon, Aug 27, 2012 • 7 Comments
A $3 Biotech Play With Recent Positive Catalysts
Bret Jensen • Sun, Aug 26, 2012 • 6 Comments
Discovery Laboratories: Company Update
Doolan Wesley • Mon, Jul 23, 2012 • 2 Comments
Discovery Laboratories: A Hidden Gem In Biotech
Doolan Wesley • Mon, May 21, 2012 • 11 Comments
Discovery Laboratories: Surfaxin Shows Compelling Advantages With Animal Surfactants
Smith On Stocks • Fri, May 4, 2012 • 7 Comments
Cash Infusions Provide Needed Financial Strength For Discovery Laboratories
Smith On Stocks • Mon, Mar 19, 2012 • 11 Comments
Surfaxin Approval Gives A Boost To Discovery Laboratories
Smith On Stocks • Wed, Mar 7, 2012 • 17 Comments
Buy Discovery Labs Before March 6 PDUFA Date
Smith On Stocks • Wed, Feb 22, 2012 • 43 Comments
Discovery Labs: Too Much Recent Turmoil
VFC's Stock House • Tue, Sep 15, 2009 • 1 Comment
Discovery Labs Anticipating Active Year End
Mike Havrilla • Fri, Sep 19, 2008
Discovery Labs: Panic at the DSCO
Michael Levin • Sun, Jun 8, 2008 • 4 Comments

SmithOnStocks Opines On Stocks: May 19th Edition
Smith On Stocks • Sun, May 19 • 12 Comments
SmithOnStocks Opines On Recent Biotech News
Smith On Stocks • Mon, May 13 • 8 Comments
Looking For Opportunity - 5 Biotechs That Crashed
Craig Keolanui • Mon, May 6 • 13 Comments
3 Biotechs With Upcoming Product Launches
Markus Aarnio • Thu, Apr 11 • 9 Comments
Investment Implications Of The Acquisition Of MAP Pharmaceuticals By Allergan
Smith On Stocks • Thu, Jan 24 • 5 Comments
2 Companies Investors Should Watch A Bit Closer As Analysts Initiate Buy Ratings
Matt Schilling • Mon, Aug 27, 2012 • 13 Comments
3 High-Growth, Low-Debt Healthcare MicroCaps
ZetaKap • Thu, Aug 23, 2012 • 2 Comments
Small Biotech Companies: Please Tread Carefully
Doolan Wesley • Tue, Jun 26, 2012
Top Micro Cap Biotech Stocks Being Accumulated By Legendary Fund Managers
GuruFundPicks • Tue, Apr 17, 2012 • 12 Comments
Time To Take Another Look At The Biotechnology Sector
BubbleBustInvesting • Mon, Apr 9, 2012 • 6 Comments
Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch
Scott Matusow • Fri, Mar 30, 2012 • 23 Comments
Opportunity On The Horizon For Discovery Laboratories Investors
Reef Anderson • Sun, Mar 25, 2012 • 25 Comments
Should You 'Sell The News' In Biotech Stocks?
BinaryLeverage • Tue, Mar 13, 2012 • 10 Comments
4 Small-Cap, High-Risk, High-Reward Bio-Pharmas
Scott Matusow • Fri, Mar 2, 2012 • 26 Comments
These Healthcare Companies Have Major March Catalysts
Spencer Knight • Thu, Mar 1, 2012 • 16 Comments
Biopharma Drug Approval Watch List
Scott Matusow • Mon, Feb 27, 2012 • 13 Comments
9 Biotech Companies With FDA Approval Decision Dates In Q1 2012
David Zanoni • Mon, Dec 12, 2011 • 3 Comments
4 Biotech Sleepers With Over 100% Upside
Epsilon • Mon, Aug 1, 2011 • 13 Comments
Top Picks by Biotech and Medical Device Focused Hedge Fund DAFNA Capital Management
GuruFundPicks • Mon, May 16, 2011 • 1 Comment
Life Sciences Companies Capture the Cash
The Burrill Report • Sun, Jun 20, 2010 • 1 Comment

Discovery Laboratories Management Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Mar 13
Discovery Laboratories Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Aug 2, 2012
Discovery Laboratories Inc. Q2 2008 Earnings Call Transcript
Sat, Aug 9, 2008

Discovery Labs Announces Completion of $14.25 Million Public Offering

PR Newswire (May 15, 2013)
Discovery Labs Prices $14.25 Million Public Offering of Common Stock

PR Newswire (May 10, 2013)
Discovery Labs Announces Proposed Public Offering of Common Stock

PR Newswire (May 9, 2013)
Discovery Labs Reports First Quarter 2013 Financial Results

PR Newswire (May 7, 2013)
Discovery Labs Receives FDA Recommendations and Request for Clarification Regarding Recently-Submitted SURFAXIN® (lucinactant) Updated Product Specifications

PR Newswire (Apr 15, 2013)
Discovery Labs Reports Fourth Quarter 2012 Financial Results

PR Newswire (Mar 13, 2013)
Discovery Labs to Report Fourth Quarter 2012 Results and Hold Conference Call on Wednesday, March 13, 2013

PR Newswire (Mar 6, 2013)
Discovery Labs Receives $30 Million Funding Commitment from Deerfield Management

PR Newswire (Feb 13, 2013)
Discovery Labs Receives New US Patent for Pulmonary Surfactant Formulations

GlobeNewswire (Jan 17, 2013)
Discovery Labs Announces Changes to Board of Directors and Appoints a New Chief Executive Officer

PR Newswire (Jan 4, 2013)
Discovery Labs Initiates Launch of AFECTAIR®

PR Newswire (Jan 3, 2013)
New Pharmacoeconomic Analysis Shows Lower Rate of Reintubation Observed With SURFAXIN® Treatment May Reduce Hospital Costs Associated with Bronchopulmonary Dysplasia

PR Newswire (Dec 4, 2012)
Discovery Labs Presents New SURFAXIN® and AFECTAIR® Data at 2012 Hot Topics in Neonatology Annual Meeting

PR Newswire (Nov 28, 2012)
Discovery Labs to Present at 2012 Piper Jaffray Health Care Conference

GlobeNewswire (Nov 20, 2012)
Discovery Labs Appoints John R. Leone to Board of Directors

PR Newswire (Nov 14, 2012)
Discovery Labs Reports Third Quarter 2012 Financial Results

PR Newswire (Nov 8, 2012)
Discovery Labs Provides Commercial Update for SURFAXIN® and AFECTAIR®

PR Newswire (Oct 24, 2012)
Discovery Labs Initiates Research Projects with Leading Research Institutions and US Government Agencies to Assess KL(4) Surfactant Utility in Acute Lung Injury

PR Newswire (Sep 27, 2012)
Newly-Published Study Compares SURFAXIN® with Animal-Derived Surfactants in Well-Established Model of RDS

PR Newswire (Sep 6, 2012)
Discovery Labs to Present at the Stifel Nicolaus Healthcare Conference 2012

GlobeNewswire (Sep 4, 2012)

DSCO vs. ETF Alternatives

Company Description

Discovery Laboratories, Inc. (referred to as “we,” “us,” or the “Company”) is a Delaware corporation, with our principal offices located at 2600 Kelly Road, Suite 100, Warrington, Pennsylvania. We were incorporated as a Delaware corporation in 1992. Our telephone number is 215-488-9300 and our... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 7, 7:58 AM Discovery Labs (DSCO): Q1 EPS of -$0.29 misses by $0.03. Revenue of $72K beats by $62K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, April 15, 5:42 PM Discovery Labs (DSCO) files a registration with the SEC to sell up to 2.34M shares of on behalf of selling shareholders. The company will not receive proceeds from the secondary offering. Comment! [Healthcare]
Monday, April 15, 1:35 PM Discovery Labs (DSCO -17%) gets slammed today after coming off an early morning halt on news the FDA had requested clarification and provided recommendations regarding the recently updated product specifications for Surfaxin, which is used to treat respiratory distress syndrome. The company says it plans to provide a response within two months, and if the FDA gives the green light, it expects to proceed with commercialization in Q413. 1 Comment [Healthcare, On the Move]
Monday, April 15, 12:50 PM Midday top 10 gainers: MKTAY +143%. CNIT +21%. GENE +21%. THRX +18%. MCOX +17%. SGRP +14%. S +13%. STXS +10%. ACOR +9%. LIFE +8%.
Midday top 10 losers: UNTK -48%. GSS -19%. ASM -18%. DSCO -17%. HXM -16%. XPL -16%. NGD -16%. TGD -15%. BAA -14%. PZG -14%. Comment! [On the Move]
Monday, April 15, 9:15 AM Premarket gainers: S +16%. SVA +13%. BCRX +10%. LIFE +8%. NFP +7%. MGT +7%. TMO +6%. THRX +5%. NVAX +5%.
Losers: AAU -15%. MTL -10%. AUQ -11%. HMY -9%. NGD -8%. CEF -8%. SLW -8%. SAND -9%. KGC -7%. AUY -7%. GOLD -7%. MUX -7%. DSCO -7%. IAG -6%. SVM -6%. GG -6%. PAAS -6%. EGO -6%. AU -5%. CDE -5%. Comment! [On the Move]
Monday, April 15, 7:59 AM Discovery Labs (DSCO) announces it received FDA recommendations and a request for clarification on Surfaxin. The company plans to provide a response to the agency within two months. DSCO halted. Comment! [Healthcare]
Monday, April 15, 7:52 AM Shares of Discovery Labs (DSCO) are halted with news pending. Comment! [Healthcare]
Sunday, April 14, 10:48 PM The rest of the top 25 June deletions from the Russell 2000 expected by Credit Suisse: QUIK, IVAC, TINY, DSCO, RLOG, RMTI, AGEN, MSPD, DRL, AXTI, ELON, GYRO, CDZI, IQNT, BSCT, UAMY, MTSN, AUMN, URZ, INOD. ''IQNT is one of the more well-owned deletes among small cap funds," says CS. Comment! [Quick Ideas]
Wednesday, March 13, 7:49 AM Discovery Labs (DSCO): Q4 EPS of -$0.16 beats by $0.12. Revenue of $195K beats by $135K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, February 14, 3:34 PM Discovery Lab (DSCO +23%) soars after inking a deal with Deerfield Management to provide up to $30M in debt financing for the biotech company. The new funds will be used to commercialize Surfaxin, which was approved last March by the FDA to treat respiratory distress syndrome in premature infants. Seeking Alpha contributor Larry Smith says the favorable terms of the financing provide a strong catalyst to buy the stock. Comment! [Healthcare, On the Move]
Thursday, February 14, 12:46 PM Midday top 10 gainers: STZ +37%. ART +32%. ANGI +24%. EMITF +21%. HNZ +20%. FFEX +20%. MEIP +18%. VCLK +17%. SPWR +17%. DSCO +16%.
Midday top 10 losers: TBAC -40%. NSPH -31%. END -31%. CTL -22%. WTW -17%. STMP -16%. STRA -11%. ULTA -11%. TCX -11%. ITRI -10%. Comment! [On the Move]
Friday, January 4, 11:34 AM Discovery Labs (DSCO -2.1%) dips after it says W. Thomas Amick has resigned as Chairman and CEO. In his stead, the board has appointed John G. Cooper as President and CEO and has been elected to the Company's board of directors, while John R. Leone is appointed Chairman of the board. 1 Comment [On the Move]
Tuesday, December 4, 2012, 2:11 PM Discovery Laboratories (DSCO +4.9%) moves up today after releasing data from a new pharmacoeconomic analysis demonstrating that the previously-reported reduced rate of reintubation in preterm infants treated with Surfaxin may also result in an average potential hospital cost savings of $389,247 per 100 treated infants by reducing the frequency of bronchopulmonary dysplasia. Comment! [Healthcare, On the Move]
Wednesday, November 28, 2012, 11:02 AM Discovery Laboratories (DSCO -3.7%) says it will present data on two of its key products, Surfaxin and Afectair, at the 2012 Hot Topics in Neonatology Annual Meeting being held December 3-4 in Washington D.C. Surfaxin is the first FDA-approved synthetic, peptide-containing surfactant for the prevention of respiratory distress syndrome in premature high risk infants, while in February 2012 Afectair, a ventilator circuit that simplifies the delivery of inhaled therapies to critical care patients requiring ventilator support, was recently cleared with the FDA for marketing in the U.S. Comment! [Healthcare]
Wednesday, October 24, 2012, 2:24 PM Discovery Lab (DSCO -12.5%) tanks after saying the commercial launch of its Surfaxin liquid medication to treat Infant Respiratory Distress Syndrome will likely be delayed until Q2 of 2013. Expectations had been for it to be released by the end of the year. 3 Comments [Healthcare, On the Move]
Wednesday, October 24, 2012, 12:45 PM Midday top 10 gainers: SEH +61%. KIPS +25%. CHC +21%. FB +21%. LL +15%. PLCM +14%. ASPS +11%. DHX +12%. MNST +13%. CYCC +12%. Top 10 Losers: TPX -22%. IRBT -19%. CPWR -16%. UIS -15%. NFLX -14%. DSCO -14%. UTHR -13%. BWLD -12%. NSM -12%. NFX -12%. Comment! [On the Move]

ZetaKap
3 High-Growth, Low-Debt Healthcare MicroCaps http://bit.ly/PfbYi1 $DSCO $INMD $RTIX @ZetaKap
8/23/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

pat50
DSCO has "golden cross" and looking good. Product has been approved did secondary so has $ now lets see how far it will run
4/26/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Winning Will
Earnings report for DSCO tomorrow. Considering a small position at 2.64. Thoughts?
3/28/12
Reply (1)

• !Report Abuse
View all 1 replies
boothy: poor
3/28/12
• !Report Abuse
Add a reply...

140 characters

reachmygoals1
Buyout Rumors? Is it possible DSCO's CEO who is a former Johnson & Johnson exec work out a deal with his old company?
3/10/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
Congratulations to czfarrah61601 for picking Discovery Labs (DSCO), who's shares jumped on approval for lung drug. http://reut.rs/zdC11H
3/7/12
Reply (3)

• !Report Abuse
View all 3 replies
Ocean Man: czfarrah also recommended AFFY a couple months ago right before it went from 5 to 8. A few weeks later it went to 11.
3/7/12
• !Report Abuse
Michael Bryant: Yeah, AFFY was another great pick.
3/7/12
• !Report Abuse
Add a reply...

140 characters

reachmygoals1
Roth Capital increased DSCO price target to $10 from $6. http://bit.ly/xrLXeK
3/7/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

1980XLS-2.0
Whoa, Look @ DSCO
3/6/12
Reply (1)

• !Report Abuse
View all 1 replies
shaker33: http://bit.ly/wShGLl
3/6/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Anybody have any news about Discovery Laboratories (DSCO)? Should one buy into or hold into Tuesday's FDA decision?
3/5/12
Reply (4)

• !Report Abuse
View all 4 replies
1980XLS-2.0: Greed is Good!
3/5/12
• !Report Abuse
Husky Financial: Michael is a very special analyst. Lets be nice!
3/5/12
• !Report Abuse
Add a reply...

140 characters

ladybell
im concern of DSCO , it will make it ?
2/29/12
Reply (1)

• !Report Abuse
View all 1 replies
Ocean Man: Disco Stu does not advertise.
2/29/12
• !Report Abuse
Add a reply...

140 characters

reachmygoals1
Surfaxin has good chance of approval on March 6. DSCO is coiling itself for a huge run soon.
2/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Winning Will
Earnings report for DSCO tomorrow. Considering a small position at 2.64. Thoughts?
3/28/12
Reply (1)

• !Report Abuse
View all 1 replies
boothy: poor
3/28/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Congratulations to czfarrah61601 for picking Discovery Labs (DSCO), who's shares jumped on approval for lung drug. http://reut.rs/zdC11H
3/7/12
Reply (3)

• !Report Abuse
View all 3 replies
Ocean Man: czfarrah also recommended AFFY a couple months ago right before it went from 5 to 8. A few weeks later it went to 11.
3/7/12
• !Report Abuse
Michael Bryant: Yeah, AFFY was another great pick.
3/7/12
• !Report Abuse
Add a reply...

140 characters

1980XLS-2.0
Whoa, Look @ DSCO
3/6/12
Reply (1)

• !Report Abuse
View all 1 replies
shaker33: http://bit.ly/wShGLl
3/6/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Anybody have any news about Discovery Laboratories (DSCO)? Should one buy into or hold into Tuesday's FDA decision?
3/5/12
Reply (4)

• !Report Abuse
View all 4 replies
1980XLS-2.0: Greed is Good!
3/5/12
• !Report Abuse
Husky Financial: Michael is a very special analyst. Lets be nice!
3/5/12
• !Report Abuse
Add a reply...

140 characters

ladybell
im concern of DSCO , it will make it ?
2/29/12
Reply (1)

• !Report Abuse
View all 1 replies
Ocean Man: Disco Stu does not advertise.
2/29/12
• !Report Abuse
Add a reply...

140 characters

DSCO Discovery Laboratories, Inc.

DSCO

Discovery Laboratories, Inc.